MedTrace Logo

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

NCT03971643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-09-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.

Conditions

  • Pyoderma Gangrenosum

Interventions

DRUG

vilobelimab

IV infusions of vilobelimab diluted in sodium chloride.

Sponsors & Collaborators

  • Innovaderm Research Inc.

    collaborator OTHER

  • InflaRx GmbH

    lead INDUSTRY

Principal Investigators

  • Prof. Niels C. Riedemann, M.D., Ph.D. · InflaRx GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-16
Primary Completion
2022-01-03
Completion
2022-01-03
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971643 on ClinicalTrials.gov